InterShunt Technologies, Inc.

InterShunt Technologies, Inc. specializes in innovative medical solutions aimed at improving heart failure treatment through advanced transcatheter technology, focusing on alleviating elevated left atrial pressure for cardiac patients. InterShunt Technologies, Inc. was founded in 2015 and is headquartered in St.

Louis, US. The company develops a proprietary transcatheter system designed to create a left-to-right atrial shunt by safely excising tissue from the interatrial septum. It has raised a total of USD 0. 89 mn in funding, with the latest round being a SERIES A from Solas BioVentures on December 3, 2021.

The company has completed two deals since its inception. Gil Fscai is the founder, while Harlee Sorkin serves as the CEO. InterShunt Technologies, Inc. specializes in the development of a proprietary transcatheter system designed to create a left-to-right atrial shunt by safely excising tissue from the interatrial septum.

This innovative device aims to alleviate elevated left atrial pressure, addressing the symptoms faced by heart failure patients. The mechanical system requires no implants or energy to operate, differentiating it from other interatrial shunting devices. The primary end users of this technology are cardiac patients suffering from heart failure, particularly those with difficulty breathing due to increased heart pressure. The company's current product, the InterShunt Percutaneous Atrial Shunt Catheter System (PAS-C), is still under development and not yet commercially available, targeting healthcare facilities and hospitals in the US with plans for global expansion upon receiving regulatory approvals.

As the InterShunt Percutaneous Atrial Shunt Catheter System is still in development and not commercially available, specific revenue data for InterShunt Technologies, Inc. is not disclosed. The company's revenue model will likely revolve around the eventual sale of its proprietary medical device to healthcare providers, which may involve direct-to-consumer transactions or partnerships with hospitals and clinics. Upon market entry, pricing structures may be influenced by production costs, healthcare reimbursement rates, and competitive analysis within the medical device sector.

The nature of these transactions could involve one-time purchases or subscription-based agreements for ongoing support and service related to the PAS-C system. InterShunt Technologies, Inc. is focused on advancing the development of its InterShunt Percutaneous Atrial Shunt Catheter System (PAS-C) with plans to launch the device once regulatory approvals are obtained. The company aims to expand into new markets, particularly targeting healthcare facilities across the US and potentially internationally.

The recent funding of USD 0. 89 mn raised in December 2021 will be utilized to further support the development and regulatory approval processes necessary for market entry.